Novel surgical sutures and novel medical devices made from novel semi-crystalline, glycolide-rich A-B-A triblock copolymers of glycolide and lactide, wherein said B-segment is a fully amorphous random copolymer of glycolide and lactide, for long term medical applications are disclosed. The novel polymer compositions are useful for long term absorbable surgical sutures, meshes and other medical devices, especially for patients with compromised healing. The novel sutures have improved properties and improved breaking strength retention, while still substantially absorbing within about a 120-day period post-implantation.

A biodegradable block copolymer has high conformability and excellent degradability. The block copolymer including a polyalkylene glycol block and a polyhydroxyalkanoic acid block, wherein the mass ratio of the polyalkylene glycol block with respect to the total mass is 10 to 60%; the carbonyl carbon has a carbon nuclear relaxation time T1 of not more than 20 ms; and the block copolymer satisfies Equation (1): =12>20 (1) 1: crystallization rate of the polyalkylene glycol block; 2: crystallization rate of a poly-A block, wherein A represents, among the repeat units contained in the polyhydroxyalkanoic acid block, a repeat unit whose homopolymer composed of the same repeat units has a highest crystallization rate.

A wound closure device can be provided as described herein. In an example, the wound closure device includes a first suture segment having a first suture configuration and a second suture segment having a second suture configuration. The first and second suture configurations can be different from each other. For example, the first suture configuration can includes a first set of characteristics such as barbed or non-barbed, barb sizes, filament sizes, colors, materials, and/or the like and the second suture configuration can include a second set of characteristics such as barbed or non-barbed, barb sizes, filament sizes, colors, materials and/or the like that can be different from the first set of characteristics. The wound closure device can further include connecting section configured to provide a transition from the first suture segment to the second suture segment.

An antimicrobial suture comprising a filament and taurolidine.

An antimicrobial suture comprising a filament and taurolidine.

Provided is an occluder, comprising a first disk-shaped structure (10) with a grid, wherein the first disk-shaped structure (10) is woven from at least two groups of braided wires, the two groups of braided wires are crossed to form multiple rings of crossing points, a blocking membrane (20) is also arranged in the disk-shaped structure (10), an edge of the blocking membrane (20) is connected to the outermost ring of crossing points (100) of the multiple rings of crossing points through a sewing wire, and the number of crossing points in the outermost ring of crossing points (100) sewn with the blocking membrane (20) is smaller than the number of all the crossing points in the outermost ring of the crossing points (100), and a position of the blocking membrane (20) near the edge thereof is connected to a ring of crossing points within the outermost ring of crossing points (100) in the multiple rings of crossing points through the sewing wire. The occluder can reduce the possibility of the phenomenon where the edge of the blocking membrane (20) cannot abut against a disk face edge of the occluder, improving the occlusion effect of the occluder.

Provided is an occluder, comprising a first disk-shaped structure (10) with a grid, wherein the first disk-shaped structure (10) is woven from at least two groups of braided wires, the two groups of braided wires are crossed to form multiple rings of crossing points, a blocking membrane (20) is also arranged in the disk-shaped structure (10), an edge of the blocking membrane (20) is connected to the outermost ring of crossing points (100) of the multiple rings of crossing points through a sewing wire, and the number of crossing points in the outermost ring of crossing points (100) sewn with the blocking membrane (20) is smaller than the number of all the crossing points in the outermost ring of the crossing points (100), and a position of the blocking membrane (20) near the edge thereof is connected to a ring of crossing points within the outermost ring of crossing points (100) in the multiple rings of crossing points through the sewing wire. The occluder can reduce the possibility of the phenomenon where the edge of the blocking membrane (20) cannot abut against a disk face edge of the occluder, improving the occlusion effect of the occluder.

Absorbable composite medical devices such as surgical meshes and braided sutures, which display two or more absorption/biodegradation and breaking strength retention profiles and exhibit unique properties in different clinical settings, are made using combinations of at least two types of yarns having distinctly different physicochemical and biological properties and incorporate in the subject construct special designs to provide a range of unique properties as clinically useful implants.

Absorbable composite medical devices such as surgical meshes and braided sutures, which display two or more absorption/biodegradation and breaking strength retention profiles and exhibit unique properties in different clinical settings, are made using combinations of at least two types of yarns having distinctly different physicochemical and biological properties and incorporate in the subject construct special designs to provide a range of unique properties as clinically useful implants.

The present invention relates to process for preparing a drug delivery composition comprising the steps of a) preparing a masterbatch comprising a drug and a first polymer by (i) extruding the first polymer, wherein said first polymer has a melting temperature below 140 C.; and (ii) introducing the drug during extrusion of the first polymer, with a drug content between 0.1% and 90%, based on the total weight of the masterbatch; and b) introducing the masterbatch in a polymer-based matrix during production of the drug delivery composition, wherein step a) is performed at a temperature at which the first polymer is in a partially or totally molten state, and step b) is performed at a temperature at which both the first polymer and at least a polymer of the polymer-based matrix are in a partially or totally molten state.